Bone Care Announces Strategic Moves in Leadership Team.

Business Editors/Health & Medical Writers

MIDDLETON, Wis.--(BUSINESS WIRE)--Nov. 18, 2002

Bone Care International, Inc. (Nasdaq:BCII) today announced two strategic moves in the leadership team intended to further enhance the business development and commercialization capabilities of Bone Care International.

Effective immediately, Basil Mundy will move into the role of Vice President, Corporate Development. Mr. Mundy will assume the responsibilities of Business Development, Advocacy Relationships and Government Affairs. "Basil brings a track record of successful industry experience and relationships to actively drive these corporative initiatives to deliver results and drive shareholder value," said Paul Berns, President and CEO.

The company also announced that Carmine Durham has been promoted to Vice President of Marketing. Mr. Durham recently joined Bone Care from the Cardiovascular Franchise at Abbott Laboratories, and previously held various management positions within the commercial sales and marketing divisions at BASF Pharma, Boehringer Mannheim Corporation and Merck. "Carmine brings the required marketing leadership expertise to support Bone Care's corporate mission of growth through execution. Carmine will play a key role in advancing our marketing objectives, including the anticipated launch of Hectorol(R) Capsules for treatment of chronic kidney disease patients not yet on dialysis. We are extremely pleased to announce these changes that reflect our on-going commitment to drive the performance of this company through world class executives and strategic leadership," said Mr. Berns.

About Bone Care International

Bone Care (www.bonecare.com) is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney, or renal disease, and osteoporosis, and other diseases including psoriasis and cancers of the prostate, breast and colon.

This press release contains forward-looking statements. Statements relating to future net sales, costs of sales, other expenses, profitability, financial resources, or products and production schedules, or statements that predict or indicate future events and trends and which do not relate solely to historical matters identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs as well as assumptions made by and information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known and unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, technical risks associated with the development of new products, regulatory policies in the United States and other countries, reimbursement policies of public and private health care payors, introduction and acceptance of new drug therapies, competition from existing products and from new products or technologies, the failure by the Company to produce anticipated cost savings or improve productivity, the timing and magnitude of capital expenditures and acquisitions, currency exchange risks, economic and market conditions in the United States, Europe and the rest of the world, and other risks associated with the Company's operations. The Company disclaims any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future events or developments.